請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/92999
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊台鴻 | zh_TW |
dc.contributor.advisor | Tai-Horng Young | en |
dc.contributor.author | 鄭銘揚 | zh_TW |
dc.contributor.author | Ming-Yang Cheng | en |
dc.date.accessioned | 2024-07-12T16:12:32Z | - |
dc.date.available | 2024-07-13 | - |
dc.date.copyright | 2024-07-12 | - |
dc.date.issued | 2024 | - |
dc.date.submitted | 2024-07-08 | - |
dc.identifier.citation | [1] M. K. Cowman, H. G. Lee, K. L. Schwertfeger, J. B. McCarthy, and E. A. Turley, "The Content and Size of Hyaluronan in Biological Fluids and Tissues," Front Immunol, vol. 6, p. 261, 2015, doi: 10.3389/fimmu.2015.00261.
[2] R. C. Gupta, R. Lall, A. Srivastava, and A. Sinha, "Hyaluronic Acid: Molecular Mechanisms and Therapeutic Trajectory," Front Vet Sci, vol. 6, p. 192, 2019, doi: 10.3389/fvets.2019.00192. [3] M. Michalczyk, E. Humeniuk, G. Adamczuk, and A. Korga-Plewko, "Hyaluronic acid as a modern approach in anticancer therapy-review," International Journal of Molecular Sciences, vol. 24, no. 1, p. 103, 2022. [4] J. Necas, L. Bartosikova, P. Brauner, and J. Kolar, "Hyaluronic acid (hyaluronan): a review," Veterinarni medicina, vol. 53, no. 8, pp. 397-411, 2008. [5] C. D. Rodriguez-Marquez, S. Arteaga-Marin, A. Rivas-Sánchez, R. Autrique-Hernández, and R. Castro-Muñoz, "A review on current strategies for extraction and purification of hyaluronic acid," International Journal of Molecular Sciences, vol. 23, no. 11, p. 6038, 2022. [6] P. Aragona, G. Di Stefano, F. Ferreri, R. Spinella, and A. Stilo, "Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjögren's syndrome patients," British journal of ophthalmology, vol. 86, no. 8, pp. 879-884, 2002. [7] F. S. Brandt and A. Cazzaniga, "Hyaluronic acid gel fillers in the management of facial aging," Clinical interventions in aging, vol. 3, no. 1, pp. 153-159, 2008. [8] R. Altman, A. Manjoo, A. Fierlinger, F. Niazi, and M. Nicholls, "The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review," BMC musculoskeletal disorders, vol. 16, pp. 1-10, 2015. [9] S. Trombino, C. Servidio, F. Curcio, and R. Cassano, "Strategies for hyaluronic acid-based hydrogel design in drug delivery," Pharmaceutics, vol. 11, no. 8, p. 407, 2019. [10] K. I. Draget, G. Skjåk-Bræk, and O. Smidsrød, "Alginate based new materials," International journal of biological macromolecules, vol. 21, no. 1-2, pp. 47-55, 1997. [11] B. Thu, P. Bruheim, T. Espevik, O. Smidsrød, P. Soon-Shiong, and G. Skjåk-Bræk, "Alginate polycation microcapsules: I. Interaction between alginate and polycation," Biomaterials, vol. 17, no. 10, pp. 1031-1040, 1996. [12] K. Y. Lee and D. J. Mooney, "Alginate: properties and biomedical applications," Progress in polymer science, vol. 37, no. 1, pp. 106-126, 2012. [13] O. Smidsrød and G. Skja, "Alginate as immobilization matrix for cells," Trends in biotechnology, vol. 8, pp. 71-78, 1990. [14] T. H. Silva et al., "Materials of marine origin: a review on polymers and ceramics of biomedical interest," International Materials Reviews, vol. 57, no. 5, pp. 276-306, 2012. [15] S. N. Pawar and K. J. Edgar, "Alginate derivatization: A review of chemistry, properties and applications," Biomaterials, vol. 33, no. 11, pp. 3279-3305, 2012. [16] J. S. Boateng, K. H. Matthews, H. N. Stevens, and G. M. Eccleston, "Wound healing dressings and drug delivery systems: a review," Journal of pharmaceutical sciences, vol. 97, no. 8, pp. 2892-2923, 2008. [17] G. T. Hermanson, Bioconjugate techniques. Academic press, 2013. [18] T. Iwasawa, P. Wash, C. Gibson, and J. Rebek Jr, "Reaction of an introverted carboxylic acid with carbodiimide," Tetrahedron, vol. 63, no. 28, pp. 6506-6511, 2007. [19] F. Kurzer and K. Douraghi-Zadeh, "Advances in the chemistry of carbodiimides," Chemical Reviews, vol. 67, no. 2, pp. 107-152, 1967. [20] N. Nakajima and Y. Ikada, "Mechanism of amide formation by carbodiimide for bioconjugation in aqueous media," Bioconjugate chemistry, vol. 6, no. 1, pp. 123-130, 1995. [21] D. H. Rich and J. SINGH, "The carbodiimide method," in Major Methods of Peptide Bond Formation: Elsevier, 1979, pp. 241-261. [22] S. K. Vashist, "Comparison of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide based strategies to crosslink antibodies on amine-functionalized platforms for immunodiagnostic applications," Diagnostics, vol. 2, no. 3, pp. 23-33, 2012. [23] D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation," cell, vol. 144, no. 5, pp. 646-674, 2011. [24] C. M. McKee et al., "Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44," The Journal of clinical investigation, vol. 98, no. 10, pp. 2403-2413, 1996. [25] D. Naor, S. Nedvetzki, I. Golan, L. Melnik, and Y. Faitelson, "CD44 in cancer," Critical reviews in clinical laboratory sciences, vol. 39, no. 6, pp. 527-579, 2002. [26] L. Y. Bourguignon, M. Shiina, and J.-J. Li, "Hyaluronan–CD44 interaction promotes oncogenic signaling, microRNA functions, chemoresistance, and radiation resistance in cancer stem cells leading to tumor progression," Advances in cancer research, vol. 123, pp. 255-275, 2014. [27] H. Shigeishi, K. Higashikawa, and M. Takechi, "Role of receptor for hyaluronan-mediated motility (RHAMM) in human head and neck cancers," Journal of cancer research and clinical oncology, vol. 140, pp. 1629-1640, 2014. [28] L. M. Pilarski, A. Masellis-Smith, A. R. Belch, B. Yang, R. C. Savani, and E. A. Turley, "RHAMM, a receptor for hyaluronan-mediated motility, on normal human lymphocytes, thymocytes and malignant B cells: a mediator in B cell malignancy?," Leukemia & lymphoma, vol. 14, no. 5-6, pp. 363-374, 1994. [29] J. A. Hinneh, J. L. Gillis, N. L. Moore, L. M. Butler, and M. M. Centenera, "The role of RHAMM in cancer: Exposing novel therapeutic vulnerabilities," Frontiers in Oncology, vol. 12, p. 982231, 2022. [30] V. Assmann, J. F. Marshall, C. Fieber, M. Hofmann, and I. R. Hart, "The human hyaluronan receptor RHAMM is expressed as an intracellular protein in breast cancer cells," Journal of cell science, vol. 111, no. 12, pp. 1685-1694, 1998. [31] S. R. Hamilton et al., "The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1, 2 that sustain high basal motility in breast cancer cells," Journal of Biological Chemistry, vol. 282, no. 22, pp. 16667-16680, 2007. [32] M. R. MacLean, O. L. Walker, R. P. Arun, W. Fernando, and P. Marcato, "Informed by Cancer Stem Cells of Solid Tumors: Advances in Treatments Targeting Tumor-Promoting Factors and Pathways," International Journal of Molecular Sciences, vol. 25, no. 7, p. 4102, 2024. [33] H. Ellis et al., "Adhesion-related hospital readmissions after abdominal and pelvic surgery: a retrospective cohort study," The Lancet, vol. 353, no. 9163, pp. 1476-1480, 1999. [34] R. M. Kamel, "Prevention of postoperative peritoneal adhesions," European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 150, no. 2, pp. 111-118, 2010. [35] G. Mage, A. Wattiez, M. Canis, J.-L. Pouly, F. Alexandre, and M. Bruhat, "Classification of adhesions," in Peritoneal surgery: Springer, 2000, pp. 221-228. [36] D. Menzies and H. Ellis, "Intestinal obstruction from adhesions--how big is the problem?," Annals of the royal college of surgeons of England, vol. 72, no. 1, p. 60, 1990. [37] S. Milingos et al., "Adhesions: laparoscopic surgery versus laparotomy," Annals of the New York Academy of Sciences, vol. 900, no. 1, pp. 272-285, 2000. [38] M. C. Parker et al., "Postoperative adhesions: ten-year follow-up of 12,584 patients undergoing lower abdominal surgery," Diseases of the colon & rectum, vol. 44, pp. 822-829, 2001. [39] W. Arung, M. Meurisse, and O. Detry, "Pathophysiology and prevention of postoperative peritoneal adhesions," World journal of gastroenterology: WJG, vol. 17, no. 41, p. 4545, 2011. [40] M.-A. Weibel and G. Majno, "Peritoneal adhesions and their relation to abdominal surgery: a postmortem study," The American Journal of Surgery, vol. 126, no. 3, pp. 345-353, 1973. [41] T. Liakakos, N. Thomakos, P. M. Fine, C. Dervenis, and R. L. Young, "Peritoneal adhesions: etiology, pathophysiology, and clinical significance: recent advances in prevention and management," Digestive surgery, vol. 18, no. 4, pp. 260-273, 2001. [42] O. L. S. Group, "Postoperative adhesion development after operative laparoscopy: evaluation at early second-look procedures," Fertility and Sterility, vol. 55, no. 4, pp. 700-704, 1991. [43] D. Menzies, "Postoperative adhesions: their treatment and relevance in clinical practice," Annals of the Royal College of Surgeons of England, vol. 75, no. 3, p. 147, 1993. [44] F. Suslavich, N. Turner, P. King, and H. K. Brown, "Intraabdominal adhesions: intraoperative US," Radiology, vol. 172, no. 2, pp. 387-388, 1989. [45] B. J. Monk, M. L. Berman, and F. Montz, "Adhesions after extensive gynecologic surgery: clinical significance, etiology, and prevention," American journal of obstetrics and gynecology, vol. 170, no. 5, pp. 1396-1403, 1994. [46] V. Mais, "Peritoneal adhesions after laparoscopic gastrointestinal surgery," World Journal of Gastroenterology: WJG, vol. 20, no. 17, p. 4917, 2014. [47] D. E. Beck, M. A. Ferguson, F. G. Opelka, J. W. Fleshman, P. Gervaz, and S. D. Wexner, "Effect of previous surgery on abdominal opening time," Diseases of the colon & rectum, vol. 43, pp. 1749-1753, 2000. [48] H. Park, S. Baek, H. Kang, and D. Lee, "Biomaterials to prevent post-operative adhesion," Materials, vol. 13, no. 14, p. 3056, 2020. [49] M. P. Diamond, "Reduction of postoperative adhesion development," Fertility and sterility, vol. 106, no. 5, pp. 994-997. e1, 2016. [50] T. R. Hoare and D. S. Kohane, "Hydrogels in drug delivery: Progress and challenges," polymer, vol. 49, no. 8, pp. 1993-2007, 2008. [51] C.-H. Chen et al., "Thermosensitive injectable hydrogel for simultaneous intraperitoneal delivery of doxorubicin and prevention of peritoneal adhesion," International journal of molecular sciences, vol. 19, no. 5, p. 1373, 2018. [52] L. A. Torres-de la Roche, V. Bérard, M. S. de Wilde, R. Devassy, M. Wallwiener, and R. L. De Wilde, "Chemically Modified Hyaluronic Acid for Prevention of Post-Surgical Adhesions: New Aspects of Gel Barriers Physical Profiles," Journal of Clinical Medicine, vol. 11, no. 4, p. 931, 2022. [53] L. M. Hablani, "Le TGF-[BETA] comme marqueur d'adhérences abdominales dans un modèle expérimental de poulain nouveau-né," 2009. [54] C. B. Brown, A. A. Luciano, D. Martin, E. Peers, A. Scrimgeour, and A. A. R. S. Group, "Adept (icodextrin 4% solution) reduces adhesions after laparoscopic surgery for adhesiolysis: a double-blind, randomized, controlled study," Fertility and sterility, vol. 88, no. 5, pp. 1413-1426, 2007. [55] C. Brochhausen et al., "Current strategies and future perspectives for intraperitoneal adhesion prevention," Journal of Gastrointestinal Surgery, vol. 16, no. 6, pp. 1256-1274, 2012. [56] Y.-C. Chuang, C.-N. Fan, F.-N. Cho, Y.-Y. Kan, Y.-H. Chang, and H.-Y. Kang, "A novel technique to apply a Seprafilm (hyaluronate–carboxymethylcellulose) barrier following laparoscopic surgeries," Fertility and sterility, vol. 90, no. 5, pp. 1959-1963, 2008. [57] Y. Ji et al., "DFT-calculated IR spectrum amide I, II, and III band contributions of N-methylacetamide fine components," ACS omega, vol. 5, no. 15, pp. 8572-8578, 2020. [58] A. Williams and I. T. Ibrahim, "Carbodiimide chemistry: recent advances," Chemical reviews, vol. 81, no. 6, pp. 589-636, 1981. [59] B. Reig-Vano, B. Tylkowski, X. Montané, and M. Giamberini, "Alginate-based hydrogels for cancer therapy and research," International Journal of Biological Macromolecules, vol. 170, pp. 424-436, 2021. [60] T. Coviello, P. Matricardi, C. Marianecci, and F. Alhaique, "Polysaccharide hydrogels for modified release formulations," Journal of controlled release, vol. 119, no. 1, pp. 5-24, 2007. [61] H. Bu, A.-L. Kjøniksen, K. D. Knudsen, and B. Nyström, "Characterization of interactions in aqueous mixtures of hydrophobically modified alginate and different types of surfactant," Colloids and Surfaces A: Physicochemical and Engineering Aspects, vol. 293, no. 1-3, pp. 105-113, 2007. [62] S.-J. Yang et al., "Folic acid-conjugated chitosan nanoparticles enhanced protoporphyrin IX accumulation in colorectal cancer cells," Bioconjugate chemistry, vol. 21, no. 4, pp. 679-689, 2010. [63] H. Hiemstra, L. Dijkhuizen, and W. Harder, "Diffusion of oxygen in alginate gels related to the kinetics of methanol oxidation by immobilized Hansenula polymorpha cells," European journal of applied microbiology and biotechnology, vol. 18, pp. 189-196, 1983. [64] M. H. Siegelman, H. C. DeGrendele, and P. Estess, "Activation and interaction of CD44 and hyaluronan in immunological systems," Journal of leukocyte biology, vol. 66, no. 2, pp. 315-321, 1999. [65] C. Chen, S. Zhao, A. Karnad, and J. W. Freeman, "The biology and role of CD44 in cancer progression: therapeutic implications," Journal of hematology & oncology, vol. 11, pp. 1-23, 2018. [66] S. Ishigami et al., "Prognostic impact of CD168 expression in gastric cancer," BMC cancer, vol. 11, pp. 1-5, 2011. | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/92999 | - |
dc.description.abstract | 玻尿酸(HA)是一個影響眾多生理功能的天然多醣,被普遍廣泛應用於臨床研究中。目前,生產玻尿酸的主要方式包括於動物組織精煉提取、微生物發酵以及酵素生產。然而,部分方式由於製造成本過高、產量較低,框架了在大量生產的可實行性。因此,尋找玻尿酸的替代生產路徑需要被高度重視。
因此設計一種化學改質方法,利用EDC反應將海藻酸鈉轉化為類似玻尿酸的材料。在合成的類玻尿酸材料(ALG_1、ALG_2和ALG_4)中,ALG_4在傅立葉轉換紅外線、氫及碳原子核磁共振光譜和元素分析中表現出與玻尿酸最為相似。此外,ALG_4對於高表達CD44和CD168的MDA-MB-231顯示出極高的生物效應,而對於低表達CD44和CD168的MCF-7細胞的影響較少,此現象使ALG_4具有癌症治療之應用的價值。 術後沾黏是術後常見的後遺症,受傷的組織持續滲血使纖維蛋白充滿整個腹腔,讓纖維細胞得以貼附。本研究透過ALG_4與海藻酸鈉水溶液充分混參並與氯化鈣交聯,成功形成了一種可被生物吸收的抗沾黏膜。此抗沾黏膜不僅在物理上有效地分離組織和器官,還能有效地減少纖維蛋白的吸附以及纖維母細胞的貼附,從而有效減輕術後沾黏的發生。 不僅提供了創新的海藻酸鈉化學改質成類玻尿酸材料的方法,更展現了ALG_4於醫學工程領域多元且廣泛的應用潛力。ALG_4作為一種類玻尿酸材料,有望其於抗沾黏、癌症治療以及其他醫學工程的應用中,成為一種能替代玻尿酸的新興的方法。 | zh_TW |
dc.description.abstract | Hyaluronic acid (HA) is a naturally derived polysaccharide that plays roles in various physiological functions and is widely used in medical applications. HA production methods primarily include extraction from animal tissues, microbial fermentation, and enzymatic production. However, some methods are often associated with high costs and low yields, limiting their industrial feasibility. Therefore, exploring alternative production routes for HA is extremely important.
This study proposes a chemical modification method using EDC reaction to make alginate into a hyaluronic acid-like material. Among the HA-like materials (ALG_1, ALG_2, and ALG_4), ALG_4 exhibited the closest similarity to HA as confirmed by FT-IR, NMR, and elemental analysis. Furthermore, ALG_4 showed significant biological effects on MDA-MB-231 which shows extremely high expresses to CD44 and CD168, while having less impact on MCF-7 cells with low expression of these markers. This indicates its potential application in cancer treatment. Postoperative adhesions are a common complication following surgery, where injured tissues continue to bleed, causing fibrin to fill the abdominal cavity and allowing fibroblasts to adhere. In this study, ALG_4 blends with alginate solution and crosslinked with calcium chloride successfully formed a bioabsorbable anti-adhesion membrane. This membrane not only physically separated tissues and organs but also significantly reduced the adhesion of fibrinogen and fibroblasts, effectively reducing the occurrence of postoperative adhesions. In conclusion, this study demonstrates an innovative chemical modification method for alginate and reveals its extensive potential applications in the biomedical field. ALG_4, as a hyaluronic acid-like material, holds promise for use in anti-adhesion, cancer treatment, and other medical applications, providing a viable solution as an alternative to current hyaluronic acid products. | en |
dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2024-07-12T16:12:31Z No. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2024-07-12T16:12:32Z (GMT). No. of bitstreams: 0 | en |
dc.description.tableofcontents | 口試委員會審定書 i
Acknowledgement ii Contents iii List of Figures viii List of Tables x 中文摘要 xi Abstract xii Chapter 1 Introduction 1 1.1 Hyaluronic acid/Hyaluronan 1 1.1.1 Properties 1 1.1.2 Sources 1 1.1.3 Applications 3 1.2 Sodium alginate 3 1.2.1 Properties 3 1.2.2 Sources 4 1.2.3 Applications 4 1.3 EDC reaction 5 1.4 Cell-extracellular matrix interaction 6 1.4.1 CD44-hyaluronic acid interaction 6 1.4.2 CD168-hyaluronic acid interaction 7 1.4.3 Breast cancer cell-hyaluronic acid interaction 7 1.5 Post-operative adhesion 8 1.5.1 Formation of adhesion 8 1.5.2 Classification of adhesion 9 1.5.3 Complications of adhesion 10 1.6 Prevention from post-operative adhesion 11 1.6.1 Hydrogels 11 1.6.2 Solutions 12 1.6.3 Membranes 12 Chapter 2 Materials and Methods 14 2.1 Materials 14 2.2 Experimental instruments 15 2.3 Analysis software 16 2.4 Methods 17 2.4.1 Preparation of HA-like material 17 2.4.2 FTIR 19 2.4.3 NMR 19 2.4.4 Elemental analysis 20 2.4.5 Cell culture 20 2.4.6 Immunofluorescence staining 21 2.4.7 Biocompatibility 21 2.4.8 Protein adsorption 22 2.4.9 Cell adhesion test 22 2.4.10 Mechanical strength 23 2.4.11 Post-operative adhesion animal model 24 2.4.12 Statistical analysis 25 Chapter 3 Results 26 3.1 Characterization of functional groups by FTIR spectra 26 3.2 Characterization of NMR spectra 27 3.3 Material composition from elemental analysis 29 3.4 Efficacy of HA-like material in CD44 and CD168 expression 30 3.4.1 Cell morphology 30 3.4.2 Cell viability 31 3.4.3 Immunofluorescence intensity of CD44 and CD168 32 3.5 Anti-adhesion membrane physical and biological testing 40 3.5.1 Mechanical strength of ALG_4 membrane 40 3.5.2 Biocompatibility of ALG_4 membrane 41 3.5.3 Protein adsorption test of ALG_4 membrane 43 3.5.4 Cell adhesion test of ALG_4 membrane 44 3.5.5 Post-operative adhesion animal model study 45 Chapter 4 Discussion 47 4.1 Preparation and characterization of HA-like material 47 4.2 Efficacy of HA-like material to breast cancer cell lines 48 4.2.1 Cell morphology 48 4.2.2 Cell viability 49 4.2.3 Immunofluorescence intensity 49 4.3 Preparation and characterization of ALG_4 membrane 50 4.3.1 Material preparation 50 4.3.2 Mechanical testing 51 4.3.3 Cell viability 51 4.4 Efficacy of ALG_4 anti-adhesion membrane 51 4.4.1 Protein adsorption test 51 4.4.2 Cell adhesion test 52 4.4.3 Animal model and anatomical evaluation 52 Chapter 5 Conclusions 54 Chapter 6 Supplementary 55 References 58 | - |
dc.language.iso | en | - |
dc.title | 以化學改質海藻酸鈉模擬玻尿酸及其生醫應用之潛力 | zh_TW |
dc.title | Chemical Modification of Alginate to Mimic Hyaluronic Acid and its Biomedical Applications Potential | en |
dc.type | Thesis | - |
dc.date.schoolyear | 112-2 | - |
dc.description.degree | 碩士 | - |
dc.contributor.oralexamcommittee | 洪智煌;施博仁;李亦宸 | zh_TW |
dc.contributor.oralexamcommittee | Chih-Huang Hung;Po-Jen Shih;Yi-Chen Li | en |
dc.subject.keyword | 玻尿酸,海藻酸鈉,化學改質,CD44,CD168,術後抗沾黏膜, | zh_TW |
dc.subject.keyword | Hyaluronic Acid,Alginate,Chemical Modification,CD44,CD168,Post-Operative Anti-Adhesion Membrane, | en |
dc.relation.page | 62 | - |
dc.identifier.doi | 10.6342/NTU202401565 | - |
dc.rights.note | 未授權 | - |
dc.date.accepted | 2024-07-09 | - |
dc.contributor.author-college | 工學院 | - |
dc.contributor.author-dept | 醫學工程學系 | - |
顯示於系所單位: | 醫學工程學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-112-2.pdf 目前未授權公開取用 | 3.7 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。